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ABSTRACT 
This research focuses on examining the neurological similarities between schizophrenia 
and major depressive disorder with psychotic features in order to compare the manifestations of 
psychosis in each disorder. Both disorders often involve symptoms of psychosis, although the 
overall disorders are very different from each other. The hypothesis for this research is that the 
neurological similarities between schizophrenia and major depressive disorder with psychotic 
features will provide researchers with the strategies needed to develop a treatment for psychotic 
symptoms. In order to test this hypothesis, five related studies were gathered for each disorder, 
and three studies were gathered for psychosis. These studies were then analyzed to pinpoint any 
similarities among factors for psychosis, and this analysis allowed for the determination of whether 
or not the hypothesis would be rejected. The results indicated that a lot of the similarities between 
the two disorders cannot be verified because of the lack of substantial research.  
Keywords: psychosis, schizophrenia, major depressive disorder with psychotic features  
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INTRODUCTION 
Schizophrenia and major depressive disorder with psychotic features (MDD-PF) are 
psychological disorders in which patients experience psychotic symptoms, also called psychosis. 
These symptoms include delusions, hallucinations, and in some cases incoherent speech or 
inappropriate behavior. Psychosis can be a scary experience, seeing as it involves what is often 
described as a “loss of touch” with reality. It can be difficult for a person experiencing psychosis 
to recognize when their experiences are not consistent with reality. If left untreated, psychosis can 
lead to social decline, paranoia, and neurological damage. Therefore, early treatment is important 
as it can lead to a better prognosis. If the possible causes for psychosis are pinpointed, this could 
lead to the development of a treatment for psychosis, potentially improving prognosis at all stages 
of development.  
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OBJECTIVE 
The purpose of this research is to identify similarities between schizophrenia and MDD-
PF. These disorders were chosen due to the fact that they are distinct enough from each other that 
any similarities may offer significance for potential causes. Other psychotic disorders such as 
schizoaffective disorder and bipolar disorder share a greater number of similarities with 
schizophrenia compared to MDD-PF. The vast difference between disorders is important because 
any factors that are shared may be directly related to psychosis, which is the most prominent 
feature that the disorders share. Factors that are compared include epidemiology, symptoms, 
treatment mechanisms, and prognosis. Any similarities between the two disorders may have 
significant implications for the treatment of psychotic symptoms, considering that psychosis is 
present in both disorders. The disorders are different enough from each other that any similarities 
may offer insight into potential diagnoses and treatments. It is likely that the causes for psychosis 
will be observable when examining the molecular backgrounds and neurological manifestations 
for each disorder. Psychosis is a symptom in which patients often experience a disconnection from 
reality (e.g., delusions or hallucinations). The causes for psychosis are not known, although there 
are theories that will be explored throughout this research. Because psychosis is displayed in the 
psychiatric disorders described, it is likely that the causes for psychosis will manifest in these 
disorders. Ideally, the potential causes for psychosis will be observable when the disorders are 
being analyzed. The hypothesis for this research is that the neurological similarities between 
schizophrenia and MDD-PF will provide researchers with strategies to develop a treatment for 
psychotic symptoms.  
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BACKGROUND 
Psychosis is said to represent the “severe” end of schizophrenia [1], seeing as schizophrenia 
is often thought to encompass some of the most damaging aspects of psychosis. Schizophrenia can 
be described as a transient disconnection from reality. MDD-PF is a form of major depression in 
which psychotic symptoms are often present. While thought to not be as “severe” as schizophrenia, 
it can also have some damaging effects. In both cases, it is important that symptoms are managed 
and treatment is ongoing. With proper treatment and emotional support, patients are able to live 
healthy and successful lives.  
SYMPTOMS, EPIDEMIOLOGY, AND DIAGNOSIS 
Schizophrenia  
Patients with schizophrenia experience two types of symptoms: positive and negative. 
Positive symptoms are perceptions that are not normally present in the general population, such as 
hallucinations and delusions. Negative symptoms occur when perceptions that are normally 
present in the general population are absent. This can include reduced emotional expression (i.e., 
constricted/flat affect), and reduced motivation (i.e., avolition) [11]. According to the Diagnostic 
and Statistical Manual of Mental Disorders, 5th edition (DSM-5), individuals must experience 
symptoms for a period of at least six months in order to be diagnosed with schizophrenia.  
Causes for this disorder are still being researched, although there are believed to be genetic 
and environmental risk factors. It is, however, difficult to determine whether specific 
environmental factors can lead to the development of schizophrenia or if these factors simply co-
occur with the disorder. For this reason, it is practical to think of environmental factors as potential 
risk factors rather than causes. There are three different “levels” of risks: highest-level risk, 
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intermediate risk, and lower-level risk [14]. The highest-level risk factors can involve having a 
direct relative with schizophrenia or having a parent who is an immigrant from a certain country. 
These factors appear to have more significance in the development of schizophrenia compared to 
intermediate and lower level risks. Intermediate risks can involve being born or raised in an urban 
area, having had a father over the age of fifty-five at the time of birth, and having minor physical 
abnormalities [2]. Lower-level environmental risk factors include the exposure to certain harmful 
agents prior to birth. For example, studies show that if a woman smokes while she is pregnant, 
there is an increased risk that the child will suffer from schizophrenia. This is similarly the case 
when a fetus is exposed to maternal stress. Interestingly, studies indicate that children born during 
the winter or early spring seasons experience a 10% increase in risk for developing schizophrenia 
[3]. Additionally, there is a strong association between maternal herpes simplex virus type 2 
antibodies and development of psychotic symptoms later in life. Children who are at risk for 
schizophrenia may have an increased risk if exposed to influenza during the mother's first trimester 
of pregnancy. One important thing to note is that a lot of these factors are simply correlated with 
the disorder; they do not indicate direct causes.  
 Some potential risk factors can occur after birth, such as childhood sexual abuse and 
traumatic brain injury. Ongoing use of cannabis in the early adolescent years (prior to age 16) 
is shown to accelerate one's risk of experiencing psychosis, as this leads to increased levels of 
dopamine [12]. In some cases, those who are susceptible develop marijuana-induced psychosis. 
The regular use of marijuana during early adolescence can therefore be thought of as a potential 
risk factor for schizophrenia. Another factor that may increase one’s risk for developing this 
disorder is withdrawal from social interaction. Studies show that those who isolate themselves are 
5 
 
at a higher risk for developing the disorder. In order to reduce one's risk of developing 
schizophrenia, individuals should avoid social isolation and seek psychological intervention if 
initial signs begin to occur, such as behavioral changes and fragmented psychotic symptoms [13]. 
This is especially important if there is a family history of schizophrenia, as this is shown to be 
correlated with higher-level risk. It is not certain whether a person must be genetically predisposed 
in order to develop the disorder. 
Childhood environment also plays an important role in the development of psychotic 
symptoms. In an Israeli study that examined childhood-rearing and its links to psychiatric 
disorders, researchers concluded that at-risk children who were raised in family environments were 
less likely to develop a psychiatric disorder compared to children who were raised in kibbutz 
environments. Children who have atypical interactions with their mothers also experience a greater 
risk for developing schizophrenia later in life. Psychotic symptoms are likely to be experienced by 
individuals who have grown up in unstable or abusive homes [14]. This does not indicate that 
childhood abuse causes psychotic symptoms, but the correlation indicates that certain 
environments can play a role in whether or not psychotic symptoms develop. Head injury is also a 
potential risk factor for psychotic symptoms. In the case of a head injury, because the brain is 
affected, a type of psychosis known as organic psychosis may occur. This is also true for cases of 
infections or illnesses that affect the brain [14].  
In order to be diagnosed with schizophrenia, patients can undergo physical examinations, 
screenings to rule out conditions with similar symptoms, and psychiatric evaluation [7]. 
Individuals should also meet the diagnostic criteria listed in the Diagnostic and Statistical Manual 
of Mental Disorders (DSM-5).  
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MDD-PF 
MDD, commonly called clinical depression, is a mood disorder in which patients 
experience constant sadness that interferes with normal functioning. MDD-PF, also known as 
psychotic depression, is considered a subset of MDD in which patients sometimes experience 
psychosis during a depressive episode. Some symptoms for the disorder include fatigue or loss 
of energy, social isolation, difficulty concentrating, and insomnia or hypersomnia [15]. Symptoms 
may differ slightly depending on the age of the patient. The epidemiology is variable, since it is 
not known exactly what causes psychotic depression. Biological changes in one’s brain, 
neurochemistry, and genetics are thought to play a role. Certain symptoms for MDD-PF may be 
associated with neurotransmitter imbalance. Researchers believe that imbalances in dopamine and 
glutamate may be present in both MDD-PF and schizophrenia, although further testing is required 
in order to confirm this. Genetic factors play an important role in the disorder, as studies 
have shown that genetic offspring are more likely to suffer from MDD-PF, as opposed to adopted 
children with no family history of depression. Twin studies have indicated that twins have a 
heritability of approximately 40-50% [5].  Poor physical health and traumatic life events are 
associated with MDD-PF, indicating that environmental factors can play a minor role. However, 
based on existing research, genetics appear to have the largest influence over whether or not an 
individual will develop the disorder.  
As mentioned previously, the use of cannabis during adolescence has been correlated with 
an increased risk of psychotic symptoms due to higher concentrations of dopamine being secreted. 
However, depression is typically associated with decreased levels of dopamine, so it is difficult to 
say whether cannabis use during the early teenage years can lead to the development of psychosis 
7 
 
in MDD-PF. Environmental factors are limited in cases of MDD-PF, mainly due to the lack of 
substantial research on the disorder. Psychosocial factors have been shown to play a role. One’s 
social environment can have an effect on the development of psychosis in MDD-PF, as social 
isolation is generally sh own to increase risk [8]. Some other factors that can lead to the 
development of psychosis mirror the environmental risk factors for schizophrenia. Child abuse and 
maternal separation can lead to the development of psychosis in individuals who are 
susceptible. Demographics indicate that MDD-PF is more common in older women and in African 
and Caribbean migrants [8].  
According to the DSM-5, patients must experience a minimum of five of the listed 
symptoms for a period of at least two weeks in order to be diagnosed with MDD. Because 
depression tends to co-occur with chronic diseases, physicians may run lab tests or do physical 
examinations on patients who show symptoms. For example, in the case of hypothyroidism, an 
underactive thyroid may cause patients to feel depressed and fatigued [16]. It is common for 
doctors to fail to diagnose hypothyroidism due to depressive symptoms being present, so it is 
important that a blood test is done in order to rule out this possibility. Physical examinations may 
also be conducted in order to rule out underlying physical health issues (i.e., diabetes or high blood 
pressure). A psychiatric evaluation may be used to diagnose the disorder.   
BIOLOGICAL FACTORS 
 As is the case with most psychiatric disorders, there are biological factors that affect the 
development and manifestation of both disorders. Schizophrenia and MDD-PF are believed to be 
influenced by both genetics and environment, although the extent to which they are influenced by 
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these factors is not known. Because genetics have an influence on each disorder, it is important to 
examine the biological factors that are involved.  
Schizophrenia  
Schizophrenia may include an imbalance in certain neurotransmitters. Some of these 
neurotransmitters include dopamine, which is responsible for motivation and reward, and 
glutamate, the primary excitatory neurotransmitter [4]. Neuroimaging can provide information 
about how the disorders relate to differences in the brain structure and/or function and can assist 
researchers with understanding the neurobiology behind each disorder. This aids in the 
development of treatments and in diagnostic procedures. A MRI study of monozygotic twins in 
which one was affected by schizophrenia and one was not showed that those affected by 
schizophrenia have larger ventricles. This is also true of those who are unaffected carriers [4]. 
Studies have also shown that those who suffer from schizophrenia have smaller 
hippocampal volumes. Change in hippocampal structure is associated with early stress, as the 
hippocampus is responsible for stress regulation [4]. Additionally, reduced white and gray 
matter are structural characteristics for schizophrenia. Individuals with schizophrenia may 
also exhibit deficiencies in parts of the brain that depend on the prefrontal cortex (PFC) [4]. This 
explains why working memory and interference control are sometimes impaired in 
individuals who suffer from this disorder.   
Biological risk factors can start as early as before birth, as minor physical anomalies 
(MPAs) are thought to play a role in developmental disorders. MPAs have been observed to have 
an increased prevalence in schizophrenic patients. Nutritional factors (i.e., low levels of vitamin 
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D) may also play a role in the development of psychosis [2]. However, these potential risk factors 
do warrant further research in order to determine whether they cause psychotic symptoms.   
MDD-PF 
MDD-PF has a heritability of approximately 40% [5]. This is likely due to the molecular 
genetics and pathophysiology of MDD. However, research on molecular genetics is fairly limited 
for cases of MDD-PF. Based on available clinical and pharmacogenetics studies, it is thought that 
MDD-PF is heavily influenced by genetics. Linkage studies indicate that there is an overlap 
between specific genetic risks for depression and schizophrenia. In a study of patients with MDD, 
it was discovered that the brain derived neurotropic factor (BDNF) val66met polymorphism has 
an association with psychotic features [6]. In contrast to MDD without psychotic features, 
additional genes were found to be associated with cases of MDD in which psychotic features were 
present. Some of these genes include single nucleotide polymorphisms in the dysbindin (DTNBPI) 
gene, the A allele of the 444G/A variant in the dopamine beta-hydroxylase (DBH) gene, and the 
active allele of the monoamine oxidase A (MAO-A) variable number of tandem repeats (VNTR) 
[6].  
Postmortem and neuroimaging studies have shown that reductions in grey matter and glial 
density in the PFC and hippocampus are characteristic of depression. High amounts of cortisol in 
MDD-PF may be explained by decreased hippocampal function, because this is thought to inhibit 
the hypothalamic-pituitary-adrenal (HPA) axis [9]. The amygdala is also affected in cases of 
MDD-PF [9]. This disorder is not as well-researched as other, more common psychological 
disorders, so there are many potential risk factors that have not been investigated. For example, 
MPAs and neurological soft signs (NSSs) are associated with schizophrenia and may be associated 
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with psychosis, but have not been investigated in cases of MDD-PF [9]. Depressive symptoms can 
occur due to physical health problems, (i.e., hypothyroidism, reduced estrogen levels, and 
disrupted circadian rhythms). 
TREATMENTS AND PREVENTION 
 There is no cure for either schizophrenia or MDD-PF, so various treatment methods are 
often used. These treatment methods include and are not limited to antipsychotics, antidepressants, 
electroconvulsive therapy, and cognitive behavioral therapy.  
Schizophrenia  
Treatments for schizophrenia often involve medications and psychosocial therapy. There 
is no cure so many patients continue to receive treatment over the course of their lives. However, 
there have been cases in which patients with schizophrenia experience spontaneous remission and 
no longer require treatment. Studies show that in cases of schizophrenia in which patients have 
made a full recovery, about 12 to 22% of these patients experience one single episode of 
schizophrenia [13]. Treatment is often guided by a psychiatrist along with a treatment team. 
Hospitalization may be necessary in extreme cases. Electroconvulsive therapy (ECT) may be 
considered effective for patients who do not respond to drug therapy. Some of the medications that 
are typically used for drug therapy can be put into two categories: first-generation and second-
generation antipsychotics [7]. Research has shown that second-generation antipsychotics may be 
associated with increased efficacy in the treatment of major depressive disorder [32]. Patients who 
use second-generation antipsychotics appear to show slight improvements in overall symptoms 
compared to first-generation antipsychotics. In particular, medications such as olanzapine, 
amilsulpride, and risperidone appear to be associated with an improved quality of life. Evidence 
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also indicates that there may be a smaller degree of side effects associated with certain second-
generation antipsychotics compared to first-generation antipsychotics. This may be dependent on 
the specific drug that is being used because some second-generation antipsychotics have shown 
associations with increased sedation or weight gain.  
Psychosocial therapy includes individual or family therapy, social skills training, or 
vocational rehabilitation. As mentioned previously, avoiding social isolation and seeking 
intervention if there are any early signs of schizophrenia can aid in prevention. Other methods for 
prevention include developing social skills, learning coping mechanisms to deal with anxiety and 
depression, and learning how to view the world more optimistically.  
MDD-PF 
Similarly to schizophrenia, there is no permanent cure for MDD-PF, but there are measures 
that can be taken to manage the symptoms. These include medications, psychotherapy, 
hospitalization, and brain stimulation therapies. Antidepressants in combination with 
antipsychotic medications may help treat the disorder, although these medications may not be 
effective until months after a patient begins taking them.  A common medication that is used to 
treat MDD-PF is selective serotonin reuptake inhibitors (SSRIs), which are antidepressants 
that increase serotonin levels and are often used in combination with antipsychotics [17]. 
Psychotherapy involves learning cognitive and behavioral skills to alleviate symptoms with a 
mental health professional. If MDD-PF is severe, typically if patients begin harming themselves 
or attempting to commit suicide, hospitalization may be necessary. ECT, which is also sometimes 
used to treat schizophrenia, is a form of brain stimulation therapy that may be utilized to treat 
MDD-PF. Prevention of the initial onset of MDD may be possible. If a person is at risk for 
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depression, undergoing cognitive or behavioral therapies may be beneficial. However, prevention 
of depression has not been studied extensively and it is a difficult disorder to prevent due to the 
genetic factors being so prominent. 
Newer forms of treatment may be developed following the discovery of new information 
regarding each disorder, including previously unknown causes and molecular markers. Molecular 
markers are crucial, because they may aid in identifying an alteration in genetic expression that 
causes susceptibility to the disorder. 
 PROGNOSIS  
For both schizophrenia and MDD-PF, prognosis is largely dependent upon the individual. 
Prognosis can be affected by a number of factors, including the severity of symptoms, how early 
intervention begins, and genetic predisposition.  
Schizophrenia  
The prognosis for schizophrenia is better when onset of the disorder is acute and treatment 
begins early. Other factors that are associated with good prognosis include demonstrating good 
premorbid functioning, being married, and exhibiting prominent affective features [13]. If 
treatment begins late and/or onset is more severe, the prognosis is grimmer. However, with proper 
treatment, those who have schizophrenia are able to live healthy, happy lives.  
MDD-PF 
Unfortunately for those who suffer from MDD-PF, the prognosis does not appear to be 
favorable. MDD-PF is thought to be a debilitating disorder with a high likelihood of recurrence. 
Because of this, it is important that patients undergo long-term treatment in order to avoid relapse. 
According to a study in which patients were examined over the course of two years, 58% of 
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patients recovered from MDD-PF while 21% had a chronic episode. The same study was 
conducted over the period of six years, in which 17% of patients experienced recovery and over 
55% had chronic episodes [10]. While prognosis can be dependent on the individual, statistical 
data indicates that a higher percentage of patients tend to experience relapse over a longer period 
of time. Prognosis is largely dependent on when treatment begins, and in order for treatment to be 
effective, it must be ongoing. Individuals who suffer from the disorder are likely to experience 
relapse.   
PSYCHOSIS 
Psychosis, rather than being its own psychological disorder, is a symptom that can occur 
within various neurological and psychiatric disorders. Causes are varied depending on the 
psychological disorder in which it manifests. In the cases of schizophrenia and MDD-PF, 
psychosis appears to be mainly genetic. Traumatic life events and consistent marijuana usage 
during early adolescence may lead to the development of psychosis, but some theories have 
speculated that individuals must be genetically predisposed in order to develop these symptoms 
[6]. Antipsychotics can effectively reduce psychotic symptoms in specific disorders, but they do 
not treat the underlying illness. Typical antipsychotics, also called first-generation antipsychotics, 
are usually less expensive than second-generation drugs, and they have been around for a longer 
period of time. It is not known which of these types of treatment is more effective, although some 
evidence suggests that second-generation antipsychotics may be associated with more improved 
symptoms.  
Dopamine and glutamate imbalance may be crucial factors in psychotic symptoms. It is 
thought that the psychopathology for psychosis is influenced by imbalance in dopaminergic 
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activity. Glutamate abnormalities have also been shown to play a role in psychosis [9]. Because 
both of these neurotransmitters are involved in schizophrenia, MDD-PF, and psychosis, they may 
play a major role in the development of psychosis. Examining the biological factors for these 
imbalances may aid in recognizing common features for the two disorders.   
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SIGNIFICANCE 
As stated previously, psychosis can have damaging effects in those who are affected. If left 
untreated, more severe health problems such as neurological damage may occur. Psychotic 
symptoms involve delusions, hallucinations, and paranoia, all of which have associations with 
being “out of touch” with reality. These can be scary for patients to experience and can often 
interfere with normal functioning. For this reason, it is important that psychotic symptoms are 
treatable. Because psychosis often requires ongoing treatment, it would benefit those who suffer 
from psychotic symptoms if a permanent cure were to be developed. By examining two slightly 
distinct disorders and comparing their manifestations of psychotic symptoms, the potential causes 
for psychosis can be identified. From here, treatments that target these specific causes would be 
able to be developed. 
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METHODOLOGY & AIMS 
This research involves a meta-analysis and systematic review approach, in which 
schizophrenia and MDD-PF and compared in order to pinpoint commonalities. Five related studies 
were gathered for each disorder, and three studies were gathered for psychosis as a symptom. 
Additional studies involving both disorders were also examined. These studies were analyzed to 
pinpoint any similarities between factors for psychosis, and this analysis allowed for the 
determination of whether or not the hypothesis would be rejected. Because this research 
emphasizes the causes for psychosis, the studies mainly focus on specific causes. This approach 
was taken because, by combining data from multiple studies and by isolating data from previous 
studies, any existing biases in previous research can be minimized. Using this method, reliable 
conclusions can be drawn. Several studies involving MDD-PF, schizophrenia, and psychosis were 
examined individually and then combined in order to analyze the consistency of the data presented. 
As stated in the hypothesis, the aim is to identify similarities that are significant enough to 
potentially be used in the development of a treatment for psychosis. Some of the factors that were 
compared include neurological similarities, cognitive effects, and pathophysiology for each 
disorder. Additionally, structural changes, neurotransmitter imbalance (i.e., dopamine and 
glutamate), and diagnostic methods were contrasted. Epidemiology and treatment mechanisms 
were also compared. The DSM-5 was frequently referenced throughout the research process, in 
addition to numerous peer-reviewed journal articles.  
 
 
  
17 
 
STUDIES 
In order to test the hypothesis for this research, recent studies were compared in order to 
determine whether the similarities between the two disorders were significant. In order to be 
considered significant, the similarities between the disorders need to offer substantial potential 
causes and additional features for psychosis. These potential causes and other features do not need 
to be various. They should simply show a reasonable amount of potential to positively influence 
the development of treatments. Studies that focused on the neurobiological factors for each 
disorder were examined. Specifically, the structural changes, molecular genetics, and functional 
impairments were examined for each disorder.  
SCHIZOPHRENIA 
Study 1: Neuropathology of Schizophrenia [20] 
 Some of the structural abnormalities that have been observed in schizophrenia include a 
decrease in cerebral volume and widening of the lateral and third ventricles. Cerebral weight is 
observed to be decreased as well. MRI studies have indicated especially large reductions in brain 
volume in the temporal lobe and in medial temporal structures, including the hippocampus and 
amygdala. Structural imaging also indicates that grey matter is more reduced compared to white 
matter. There is speculation that patients with schizophrenia have a reduction in the size of the 
thalamus. It has also been reported that patients experience structural abnormalities in the 
cerebellum, although further research must be done to confirm either of these theories. 
Study 2: Dopamine Hypothesis of Schizophrenia: Version III – The Final Common Pathway [21] 
 This hypothesis seeks to explore the question of whether symptoms in schizophrenia are 
related to dysfunctions in the regulation of dopamine. There is emphasis on the possibility that 
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dopamine may play a dominant role in psychosis. Version III is the most recent version of this 
hypothesis since it accounts for the most recent knowledge about dopamine’s role in 
schizophrenia. It is expected to be revised in the future as research continues to be conducted on 
factors associated with schizophrenia. This study emphasizes the fact that there are environmental 
factors correlated with schizophrenia that cannot be explained by genetics. For example, it has 
been observed that increased dopaminergic activity can result from factors such as social isolation. 
Because both genetic and environmental factors are shown to play a role in dopamine 
dysregulation in schizophrenia, it is thought that these factors work together to influence 
dopaminergic functions. This in turn may have an effect on symptoms in schizophrenia.  
Study 3: Molecular Genetics of Schizophrenia [27] 
  This study focuses on linkage studies, neurotransmitter responses, and other factors in 
order to observe the molecular genetics of schizophrenia. Neurotransmitters such as dopamine, 
serotonin, and glutamate have been shown to have a role in schizophrenia. Amino acids such as 
glycine and cysteine also have manifestations in the disorder. The D3 dopamine receptor gene is 
present in high concentrations in the limbic system so it may have a large role in schizophrenia. 
However, studies have not been able to confirm the dopamine theory. Glutamate appears to show 
evidence of an association with schizophrenia. Patients with schizophrenia display reduced non-
NDMA glutamate receptors in the temporal lobe compared to individuals who do not have 
schizophrenia. Studies have also demonstrated that patients with schizophrenia have reductions in 
serotonin receptors in the PFC. The serotonin transporter gene is also shown to be involved with 
psychosis. It is possible that other neurotransmitters such as GABA are associated with 
schizophrenia, but existing evidence is too weak to allow for any conclusions to be made.  
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Study 4: Prefrontal Functioning during Context Processing in Schizophrenia and Major 
Depression [29] 
 It has been observed that patients with schizophrenia exhibit decreased cerebral blood flow 
in the prefrontal cortex, called hypofrontality. This study seeks to find out whether hypofrontality 
occurs only in schizophrenia or if it manifests in other psychotic disorders. Results indicated that 
patients with schizophrenia exhibit larger reductions in cognition than patients with non-psychotic 
depression. It is uncertain whether dysfunctions related to context processing in the prefrontal 
cortex are specific to cases of schizophrenia, or if these dysfunctions appear in other psychiatric 
disorders.  
Study 5: Cognitive Impairments in Psychotic Disorders [18] 
 This study asserts that patients with schizophrenia experience a higher degree of 
impairment to cognitive abilities compared to patients with MDD-PF and other psychiatric 
disorders such as bipolar disorder. These disorders do still involve an impairment to cognitive 
function, but the impairment is less severe than as observed in schizophrenia. In the case of 
schizophrenia, working and episodic memory are affected, partly due to the fact that the prefrontal 
cortex is impaired and has difficulty communicating with other regions of the brain. Schizophrenia 
appears to display a higher amount of cognitive impairment than affective psychosis, although the 
overall degree of cognitive impairment seen in schizophrenia and psychosis is very similar. Results 
indicate that all psychotic disorders involve cognitive damage at some level.  
MDD-PF 
Study 1: Clinical and Molecular Genetics [23] 
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 This study explores the inheritance of psychotic depression with reference to family 
studies, other psychotic disorders, and molecular genetics including pharmacogenetics studies. 
Dopamine has been observed to play a role in the development of MDD-PF. The dopamine beta-
hydroxylase gene is reported to show lower plasma levels in patients with psychotic depression 
when compared to patients with nonpsychotic depression. Glutamate may be linked to MDD-PF 
but it is not certain whether increased or decreased glutamate concentration is associated with the 
onset of the disorder. Serotonin receptors and transporter have been shown to not have an 
association with MDD-PF. Genetic and family studies do indicate that psychotic depression is 
often inherited and may be heavily influenced by genetics. This highlights part of the reason why 
it is so important that genetic research continues to be conducted on this disorder. 
Study 2: Structural and Functional Neuroimaging Studies in Major Depressive Disorder with 
Psychotic Features [25] 
 This study focuses on the pathophysiology for psychotic disorders such as MDD-PF and 
schizophrenia, with a particular emphasis on MDD-PF. Structural changes in patients with MDD-
PF are observed in proportion to changes in MDD without psychotic features. One structural 
change seen only in MDD-PF patients involves a reduction in the size of the amygdala. Enlarged 
ventricles and reductions in the volume of the prefrontal cortex were also observed. A distinction 
in structural features between MDD-PF and schizophrenia includes a reduction in size of the 
posterior subgenual cingulate cortex (in the medial side of the cerebral cortex) in patients with 
MDD-PF. There is evidence that dysfunctions in dopamine may be present in cases of MDD-PF, 
although the extent to which this influences the disorder is unknown.  
Study 3: Cortisol Activity and Cognitive Changes in Psychotic Major Depression [26] 
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 This study built on the fact that MDD-PF is a distinct disorder rather than simply a subset 
of MDD. While this disorder is technically a subset of MDD, there are features present that are not 
present in MDD, indicating that MDD-PF can be considered to be distinct from MDD without 
psychotic features. In this study, patients with MDD, patients with MDD-PF, and individuals 
without psychiatric disorders were each given a memory test. Memory was shown to be worse in 
patients with MDD-PF than in either of the other groups. Studies also indicate that patients with 
MDD-PF have greater degrees of cognitive impairments that those with MDD without psychotic 
features. This includes problems with prefrontal functions and memory.  
Study 4: Hippocampal and Amygdalar Volumes in Psychotic and Nonpsychotic Unipolar 
Depression [30] 
 According to this study in which the hippocampal and amygdalar volumes in patients with 
major depressive disorder (MDD) without psychotic features and MDD-PF were compared, it was 
demonstrated that patients with MDD-PF had much smaller amygdalar volumes. The amygdalar 
volume in patients with MDD was shown to be similar to healthy subjects. There was no significant 
difference in hippocampal volumes between the groups.  
Study 5: Dopaminergic Function and the Cortisol Response to Dexamethasone in Psychotic 
Depression [31] 
 This study tested the hypothesis that psychotic symptoms in MDD-PF could result from 
increased dopamine activity. After the cortisol and hormonal responses to DST suppressors and 
activators were examined, the conclusion was that psychotic symptoms in MDD-PF do not appear 
to be related to dopamine regulation.  
PSYCHOSIS 
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Study 1: Disconnection between Amygdala and Medial Prefrontal Cortex in Psychotic Disorders 
[22] 
 A common characteristic that appears in psychotic disorders is an impairment in cognitive 
functioning, including deficits in memory and reduced amygdalar functioning. These factors are 
enhanced in response to distracting emotional information such as unemployment. When patients 
who suffer from psychotic disorders experience an emotional distractor, a reduction in connectivity 
between brain regions has been observed, with a particular increase in reduction of brain structures 
in cases of schizophrenia.  
Study 2: Dopamine and Psychosis [24] 
 Studies have shown that psychosis may be triggered by a dysfunction in dopamine 
synthesis, as stated in the dopamine hypothesis of schizophrenia. This study focuses on the links 
between psychosis and dopamine activity. Some studies suggest that psychosis is affected by 
factors other than dopamine activity such as prefrontal functioning. There are implications that 
these additional factors occur alongside dopamine dysfunction. Schizophrenia’s link with 
psychosis and dopamine was extensively researched in this study, and results indicate that 
excessive dopamine activity may lead to the cognitive impairments seen in schizophrenia. These 
impairments include those that occur in working memory, abstract reasoning, and other cognitive 
functions that rely on the prefrontal cortex. Based on the results that were gathered in this study, 
it is plausible that dopamine plays a central role in the psychotic symptoms seen in schizophrenia 
and other psychotic disorders.  
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Study 3: Progressive Brain Structural Changes Mapped as Psychosis Develops in ‘At Risk’ 
Individuals [28] 
 This study emphasizes findings that indicate that individuals who are at risk for developing 
psychotic disorders display progressive structural changes in the brain prior to developing the 
disorder. Results indicate that those who experience psychosis demonstrate much greater changes 
in brain structure in the prefrontal cortex than any other region of the brain, even before symptoms 
of a psychotic disorder developed. This implies that reductions in the volume of the prefrontal 
cortex may be associated with the development of psychosis. 
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RESULTS 
It is important to note that patients with MDD-PF exhibit a reduction in size of the posterior 
subgenual cingulate cortex, while patients with schizophrenia do not. Because this feature is not 
seen in either schizophrenia or psychosis, it is likely the result of depressive features rather than 
psychotic features. This emphasizes the fact that patients with MDD-PF are less likely to display 
certain psychotic features compared to schizophrenia, since MDD-PF has an additional feature 
(depression) that is not displayed in either schizophrenia or psychosis. This distinction enables 
effective comparison of certain features in order to determine whether or not they are significant, 
since the disorders are different enough that any similarities they have may be significant for the 
hypothesis.  
The factors that were compared when examining the studies include structural changes, 
molecular backgrounds, and other biological factors. Multiple studies have concluded that there 
are changes in brain volume in schizophrenia as well as in MDD-PF. Specifically, it has been 
shown that amygdalar volume as well as hippocampal volume are reduced in patients with 
schizophrenia. Patients with MDD-PF have been shown to have large reductions in amygdalar 
volume, but no significant changes in hippocampal structure compared to those who are not 
affected with MDD without psychotic features. Whether or not this decrease in amygdalar volume 
is significant is largely dependent on whether psychosis as a symptom is affected by structural 
changes in the amygdala. Based on existing research, a reduced amygdalar volume does appear to 
be related to psychosis, so this factor could plausibly be considered significant. Other structural 
changes that are observed in both disorders include enlarged ventricles and reduction in volume of 
the prefrontal cortex. Because these factors are consistent in both disorders and in psychosis as a 
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symptom, they may be significant for the hypothesis. However, in order to be considered 
significant, there must be additional supporting data since these structural brain changes may be 
associated with another common denominator. 
Table 1: Structural Brain Changes Associated with Schizophrenia and MDD-PF 
Brain Structure MDD-PF Schizophrenia   
Cerebrum  Reduced blood flow Reduced blood flow  
Prefrontal cortex Reduction in volume Reduction in volume 
Amygdala Reduction in volume Reduction in volume 
Hippocampus  No significant change Reduction in volume 
Posterior subgenual cingulate 
cortex 
Reduction in volume No significant change 
Ventricles Enlarged Enlarged  
Thalamus No significant change Possible association 
Cerebellum  No significant change Possible association  
White matter Disrupted  Reduced 
Gray matter Disrupted  Reduced to a higher degree 
compared to white matter 
 
The molecular backgrounds for each disorder include associated neurotransmitters and 
hormones. One study concluded that dopamine dysregulation is not related to psychotic symptoms 
in MDD-PF. This is in contrast to the dopamine hypothesis of schizophrenia, in which it is thought 
that dopamine dysregulation may have a role in the development of schizophrenia. However, there 
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is another study that concluded that dopamine dysregulation may be associated with MDD-PF, but 
this study specifically highlighted reduced concentrations of dopamine having an association. 
Schizophrenia, on the other hand, is associated with increased dopamine secretion. This study does 
not offer reliable evidence that MDD-PF is indeed associated with decreased dopamine secretion 
because another study concluded that the linkage may be insignificant or even nonexistent. Since 
dysfunctions in dopamine activity in MDD-PF patients may not be related to psychosis, it cannot 
be concluded that dopamine is a direct cause for psychosis, regardless of dopamine’s association 
with psychosis in other psychotic disorders. Because the research regarding dopamine’s role in 
MDD-PF is relatively limited, it is possible that dopamine has a larger role that has not been studied 
yet. This may especially be the case since the dopamine hypothesis of schizophrenia highlights the 
fact that current evidence is consistent with the possibility of dopamine dysfunction playing a 
central role in psychosis. Since this is only a speculation, the dopamine hypothesis is not significant 
enough to support the hypothesis for this research. Other neurotransmitters such as serotonin and 
glutamate were shown to have greater effects in one disorder compared to the other, or had 
associations that were not consistent with each other. Therefore, this factor can be disregarded as 
a supporting factor for the hypothesis.  
Table 2: Molecular Structures Associated with Schizophrenia and MDD-PF 
Molecular Structure MDD-PF Schizophrenia   
Cortisol  Increased concentrations  Increased concentrations  
Serotonin transporter No association  Reduced  
Serotonin receptor 1A No association  Reduced 
Serotonin receptor 2A No association  Reduced 
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Table 2: Molecular Structures Associated with Schizophrenia and MDD-PF 
Serotonin receptor 2C No association  Reduced 
Dopamine beta-hydroxylase  Decreased concentrations  Decreased concentrations  
D1 receptor Possible reduction   May be associated with 
reductions in the prefrontal 
cortex 
D2 receptor Possible reduction   Increased concentrations  
D3 receptor  Possible reduction   Increased concentrations; 
weak association  
5-hydroxytrytamine; 5HT No association  Findings are inconsistent but 
indicate a possible association 
with negative symptoms and 
ventricular enlargement 
Glutamate and Glutamine 
combined 
Possible association  Increased concentrations 
especially as patients age; 
associated with positive 
symptoms  
Dopamine transporter Possible reduction   No association  
Non-NDMA glutamate 
receptors 
Possible association  Reduced  
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Cognitive impairments are associated with both schizophrenia and MDD-PF, although 
patients with schizophrenia display higher degrees of damage. On its own, psychotic symptoms 
are associated with cognitive impairments that have very similar profiles to the impairments 
displayed in schizophrenia. Since these impairments in psychosis are more similar to schizophrenia 
than to MDD-PF, it is difficult to say whether this factor could be considered significant for the 
hypothesis. It is possible that those with MDD-PF display diminished amounts of cognitive 
impairment because psychotic features are a “smaller portion” of the disorder compared to 
schizophrenia. Patients with MDD-PF often experience psychotic symptoms in addition to 
depression, which sets it apart from both schizophrenia and psychosis. Schizophrenia, on the other 
hand, is almost considered to be synonymous with psychosis, so it is expected that schizophrenia 
and psychosis would display a greater amount of similar features. However, because this 
possibility is hypothetical, cognitive impairment will not be considered as a significant supporting 
factor.  
 In terms of epidemiology, symptoms, and prognosis, any similarities would be considered 
insignificant because these factors would not reasonably provide information needed that would 
aid in the development of permanent treatments. Treatments would be best developed to target 
certain neurotransmitters or structural deficiencies in the brain. It would not be practical to expect 
a treatment to potentially be derived based on information related to epidemiology and similar 
factors. Current treatments can offer insight into ways that symptoms can be managed but the 
development of cures is mainly dependent on genetic research.  
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CONCLUSION 
 Based on the information that was gathered, the hypothesis for this research must be 
rejected. Unfortunately, the amount of existing research regarding the disorders, especially MDD-
PF, is very limited. Because of this, many of the similarities between MDD-PF and schizophrenia 
are speculative rather than definite. With so many gray areas in current research, it is difficult to 
pinpoint exactly what needs to be targeted in the treatment of psychosis. The hypothesis may 
possibly be more strongly supported in the future after substantial research is conducted on each 
disorder. For the time being, there is not enough available information for any reliable conclusions 
to be drawn regarding possible treatments.  
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DISCUSSION 
 Both schizophrenia and MDD-PF appear to be affected by both genetic and environmental 
factors, although the extent to which each disorder is affected is unknown. MDD-PF has 
demonstrated a high degree of heritability so it is possible that the disorder is more strongly 
affected by genetics compared to environmental factors. Psychosis is also shown to be affected by 
genetics and environment. Because of this, it was important to address both the genetic and 
environmental risk factors for each disorder when conducting this research. The genetic 
similarities are more likely to offer support for the hypothesis, considering the fact that medicinal 
treatments can directly target biological factors such as structural abnormalities and 
neurotransmitter imbalance. Environmental factors are better treated with psychological therapies 
and cannot be directly targeted. 
Some of the similarities that have been pinpointed include structural abnormalities and 
neurotransmission. Patients with MDD-PF and patients with schizophrenia demonstrate reduced 
prefrontal volumes, smaller amygdalar structures, and dilated ventricles. Dopamine may have 
associations with each disorder although further research must be conducted in order to confirm 
this. Serotonin and glutamate are shown to have associations with schizophrenia and either reduced 
or no associations with MDD-PF. With regards to cognitive impairments and the effects of 
dopamine, the differences between the disorders outweigh the similarities. While both disorders 
display deficits in cognitive functioning and dysregulation of dopamine, the disorders are not 
affected to the same extent and certain factors manifest themselves in different ways.  
Due to the limitations in current research, there are a lot of uncertainties and hypotheticals 
when examining the similarities between MDD-PF and schizophrenia. For example, the structural 
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abnormalities could hypothetically be a cause for psychosis assuming that there is no other 
common denominator. Since it is not known whether these abnormalities are associated with a 
completely different aspect of each disorder, it is best to reject this as a potential cause. Although 
the hypothesis was rejected, this does not mean that it will never be supported by data or that it 
will always be rejected. Considering that the largest problem when gathering data was that there 
is a lack of considerable research, the hypothesis may be better supported in the future, assuming 
that substantial research will be done on both disorders, as well as on psychosis on its own.  
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LIMITATIONS 
There is currently a lack of considerable research regarding psychosis and MDD-PF. 
Schizophrenia has been researched more thoroughly, but there is still a lot that is not known about 
the disorder. Because this research was based primarily on existing research, it was at times 
difficult to find exact data regarding the biological background for schizophrenia and MDD-PF. 
Many of the potential genetic causes for the disorders were not definite causes; rather, they were 
considered potential risk factors or associated factors. Additionally, some environmental factors, 
potential causes, and diagnoses for each disorder, as well as for psychosis, were under-researched. 
Because of this, many of the comparisons made throughout this research were hypothetical and 
unconfirmed.  
One other limiting factor in this research is the fact that a lot of studies relate psychosis 
directly to schizophrenia. This made it difficult to find studies that focused primarily on psychosis. 
For example, many studies referenced the dopamine hypothesis of schizophrenia and some studies 
had a slight implication that dopamine dysregulation was related to psychotic symptoms. However, 
this may only be the case for some psychotic disorders, since one study indicated that it was 
unlikely that the psychotic symptoms in MDD-PF are associated with dopamine dysregulation.  
This lack of research on psychosis on its own made it difficult to compare symptoms of psychosis 
in MDD-PF and schizophrenia, since psychosis and schizophrenia were often studied so closely 
in relation to each other.   
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